Back to top
more

Cara Therapeutics, Inc. (CARA)

(Delayed Data from NSDQ)

$19.38 USD

19.38
391,191

+0.52 (2.76%)

Updated Oct 15, 2019 03:57 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | C Growth | C Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for CARA

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Cara Therapeutics, Inc. [CARA]

Reports for Purchase

Showing records 1 - 20 ( 28 total )

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CARA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

08/12/2019

Company Report

Pages: 7

2Q19 KALM-2 Interim Powering Update Next Couple Months

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

07/22/2019

Company Report

Pages: 6

Oral Korsuva Phase 2 Enrolled; Confirmed Power Increases Confidence in Positive Results Like IV Korsuva; Raise to $31

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/29/2019

Company Report

Pages: 9

Positive KALM-1 Data in CDK-aP Bodes Extremely Well for KALM-2 and Eventual CKD-aP Approval; Raise Target to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/09/2019

Company Report

Pages: 10

Keep Calm: Expect Positive KALM-1 Phase 3 Data Imminently; KALM-2 Interim Powering Analysis Also on Tap

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/13/2019

Company Report

Pages: 7

Confident in Positive Korsuva Pivotal Data Within 3 Months; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/03/2019

Company Report

Pages: 8

Positive Korsuva Interim Powering Look Should Provide Material Sentiment Boost; Expect Outperformance into 2Q19 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/08/2018

Company Report

Pages: 7

3Q18 Results; Plowing Forward With CKD-aP Phase 3s; First Pivotal Data in 1H19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

08/08/2018

Company Report

Pages: 7

2Q18 Results; Pruritus Programs on Plan; Funded Well Past Key Data; CMS Payment Proposal Should De-Risk Initial Uptake

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

06/28/2018

Company Report

Pages: 6

Surprising Positive Post-Op Pain Data Provides Some Upside Optionality; Raise to $26

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/23/2018

Company Report

Pages: 9

Premier Partnership Incrementally De-Risks IV Korsuva; Reiterate Buy and Raise to $24

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/11/2018

Company Report

Pages: 7

1Q18 Results; Pruritus Pipeline Progressing on Plan

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/19/2018

Company Report

Pages: 8

4Q17 Results; Pruritus Plans on Track; Pain Played Down; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/12/2018

Company Report

Pages: 14

Looking Past Pain to Pruritus; Transfer Coverage With a Buy and $22 Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 50.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/04/2017

Company Report

Pages: 7

CR845: Coming to a Pruritus Near You Ahead of Post-Op Pain Data in 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

07/13/2017

Daily Note

Pages: 3

Oral ''845 for Itch Is Off to the Races With Phase 1 Bioequivalency Cleared

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

06/30/2017

Company Report

Pages: 5

This Is Why You Do Phase 2-a Clear Positive Signal Warrants Forging Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

06/22/2017

Company Report

Pages: 5

IV ''845 Interim Look in Post-Op Pain Says Press On; P2 Oral in OA Pain in Coming Days

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/17/2017

Daily Note

Pages: 4

Itching for Pain Data and Just Scratching the Surface of ''845''s Potential

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Cara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/05/2017

Company Report

Pages: 6

This Is Now the Quarter of Pain

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party